2-Fluoro-N-methylaniline | CAS:1978-38-7

We serve 2-Fluoro-N-methylaniline CAS:1978-38-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Fluoro-N-methylaniline

Chemical Name:2-Fluoro-N-methylaniline
CAS.NO:1978-38-7
Synonyms:2-Fluoro-N-methylaniline
N-methyl-o-fluoroaniline
n-methyl-2-fluoroaniline
Molecular Formula:C7H8FN
Molecular Weight:125.14400
 
Physical and Chemical Properties:
Density:1.106
Boiling point:87-88ºC
Flash point:62.9ºC
 
Specification:
Appearance:Yellow clear liquid
Assay:≥99.0%
Moisture:≤0.2%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 2-Fluoro-N-methylaniline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,n-methyl-2-fluoroaniline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,n-methyl-2-fluoroaniline Use and application,n-methyl-2-fluoroaniline technical grade,usp/ep/jp grade.


Related News: Slow business: Due to fear — and travel warnings — fewer people want to travel to China.2-methoxy-5-nitrobenzenediazonium manufacturer Slow business: Due to fear — and travel warnings — fewer people want to travel to China.dimethyl-bis[[methyl(diphenyl)silyl]oxy]silane supplier In addition, with the increase of environmental protection pressure, nearly one hundred Beijing pharmaceutical companies have gathered in the Bohai Bay, and the raw material drug base in northern China has taken shape.2,4-Dichlorophenylboronic acid vendor In addition, with the increase of environmental protection pressure, nearly one hundred Beijing pharmaceutical companies have gathered in the Bohai Bay, and the raw material drug base in northern China has taken shape.An analysis of the top 20 global companies by R&D spend for 2018 shows that companies with expensive late-stage pipeline drugs are spending significant proportions of their annual revenue on R&D.